These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35745835)

  • 21. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L; Wang XI; Ding J; Sun Q; Zhang S
    Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineering Cell Membrane-Based Nanovesicles for Melanoma Tumor Treatment.
    Xin S; Wu Y; Huang Z; Huang Y; Jia B; Zhao J
    J Biomed Nanotechnol; 2021 May; 17(5):838-845. PubMed ID: 34082870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment.
    Yang ZY; Jiang CW; Zhang WL; Sun G
    J Transl Med; 2022 Jun; 20(1):276. PubMed ID: 35717238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. (-)-Sativan Inhibits Tumor Development and Regulates miR-200c/PD-L1 in Triple Negative Breast Cancer Cells.
    Peng F; Xiong L; Peng C
    Front Pharmacol; 2020; 11():251. PubMed ID: 32231566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1
    Mohan N; Hosain S; Zhao J; Shen Y; Luo X; Jiang J; Endo Y; Wu WJ
    Oncoimmunology; 2019; 8(9):e1624128. PubMed ID: 31428520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy.
    Jabbarzadeh Kaboli P; Salimian F; Aghapour S; Xiang S; Zhao Q; Li M; Wu X; Du F; Zhao Y; Shen J; Cho CH; Xiao Z
    Pharmacol Res; 2020 Jun; 156():104806. PubMed ID: 32294525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
    García-Teijido P; Cabal ML; Fernández IP; Pérez YF
    Clin Med Insights Oncol; 2016; 10(Suppl 1):31-9. PubMed ID: 27081325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational combination of immunotherapy for triple negative breast cancer treatment.
    Li CW; Lim SO; Hsu JL; Hung MC
    Chin Clin Oncol; 2017 Oct; 6(5):54. PubMed ID: 29129094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
    Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
    Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intelligent Biomimetic Nanoplatform for Systemic Treatment of Metastatic Triple-Negative Breast Cancer
    Wang X; Zhu X; Li B; Wei X; Chen Y; Zhang Y; Wang Y; Zhang W; Liu S; Liu Z; Zhai W; Zhu P; Gao Y; Chen Z
    ACS Appl Mater Interfaces; 2022 May; ():. PubMed ID: 35549005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
    Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
    Qin G; Wang X; Ye S; Li Y; Chen M; Wang S; Qin T; Zhang C; Li Y; Long Q; Hu H; Shi D; Li J; Zhang K; Zhai Q; Tang Y; Kang T; Lan P; Xie F; Lu J; Deng W
    Nat Commun; 2020 Apr; 11(1):1669. PubMed ID: 32245950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Augmentation of antitumor function of tumor-infiltrating lymphocytes against triple-negative breast cancer by PD-1 blockade.
    Song H; Wang H; Gong M; Wu L; Liu X; Cao W; Gao X; Dou R; Chen Q; Hu H
    Cell Biol Int; 2022 Feb; 46(2):278-287. PubMed ID: 34854515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed cell death ligand - 1 expression in triple negative breast carcinoma and its prognostic significance in Indian population.
    Gajaria PK; Gupta MR; Patil A; Desai SB; Shet TM
    Indian J Pathol Microbiol; 2021; 64(4):664-670. PubMed ID: 34673583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose metronomic gemcitabine pretreatments overcome the resistance of breast cancer to immune checkpoint therapy.
    Zheng X; Kuai J; Shen G
    Immunotherapy; 2023 Apr; 15(6):429-442. PubMed ID: 36880262
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.